Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


When insulin isn’t enough: targeting glucagon in type 1 diabetes


A phase 2 study fails to meet its primary endpoint, but the treatment — a glucagon receptor antagonist — shows clinically relevant improvements in glycemic control, warranting further investigation as a potential adjunct to insulin.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Meal-related glycemic excursions despite insulin therapy.


  1. Foster, N. C. et al. Diabetes Technol Ther. 21, 66–72 (2019).

    Article  CAS  Google Scholar 

  2. Pettus, J. et al. Nat. Med. (2022).

    Article  PubMed  Google Scholar 

  3. Unger, R. H. & Orci, L. Proc. Natl Acad. Sci. USA 107, 16009–16012 (2010).

    Article  CAS  Google Scholar 

  4. Brown, R. J., Sinaii, N. & Rother, K. I. Diabetes Care 31, 1403–1404 (2008).

    Article  CAS  Google Scholar 

  5. Sherr, J. et al. Diabetes Care 37, 1741–1744 (2014).

    Article  Google Scholar 

  6. Gerich, J. E. et al. Science 182, 171–173 (1973).

    Article  CAS  Google Scholar 

  7. Pearson, M. J., Unger, R. H. & Holland, W. L. Diabetes Care 39, 1075–1077 (2016).

    Article  Google Scholar 

  8. Kelly, R. P. et al. Diabetes Obes. Metab. 17, 414–422 (2015).

    Article  CAS  Google Scholar 

  9. Pettus, J. et al. Diabetes Obes. Metab. 20, 1302–1305 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jennifer Sherr.

Ethics declarations

Competing interests

M.A.V. reports research support from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and Provention Bio. J.L.S. reports research support from the Juvenile Diabetes Research Foundation, Insulet, Medtronic and NIDDK; has served on advisory boards for Bigfoot Biomedical, Cecelia Health, Insulet, Medtronic Diabetes, StartUp Health Diabetes Moonshot and Vertex; and has done consulting work for Cecelia Health, Eli Lilly, Insulet, Medtronic and Zealand.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Van Name, M., Sherr, J. When insulin isn’t enough: targeting glucagon in type 1 diabetes. Nat Med 28, 2007–2008 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing